Quick Facts

• Primary Use: Management of Amyotrophic Lateral Sclerosis (ALS) associated with the SOD1 gene mutation.
• Therapeutic Role: Contributes to the clinical care protocol for this specific inherited condition.

---

What Supernide Treats: Main Uses and Benefits

Supernide is utilized as a treatment option for adults diagnosed with Amyotrophic Lateral Sclerosis (ALS) who possess a documented mutation in the superoxide dismutase 1 (SOD1) gene. This specific form of the condition is a progressive neurodegenerative disorder affecting the nerve cells responsible for controlling voluntary muscles.

The administration of Supernide in this context is intended to address the underlying factors related to the genetic mutation. It is part of the overall therapeutic management strategy for patients with this rare, inherited form of ALS.

The use of Supernide has been associated with a reduction in a specific biomarker of nerve injury (neurofilament light chain, or NfL) in the bloodstream. This change in the surrogate endpoint is considered reasonably likely to suggest a clinical benefit for patients, supporting its role in the management of this condition.

Supernide is officially allowed only for adults with Type 2 Diabetes Mellitus to be used as an adjunct to diet and exercise. Regulatory documents establish clear restrictions regarding its use in specific populations and clinical conditions.

The medicine is contraindicated and must not be used by patients diagnosed with Type 1 Diabetes Mellitus or Diabetic Ketoacidosis. Absolute prohibitions also extend to individuals with a known hypersensitivity to repaglinide or excipients, those with Severe Hepatic Function Disorder, and patients taking the medication Gemfibrozil concurrently.

Use of Supernide is not recommended for several groups: children and adolescents under 18 years of age, patients over 75 years (due to insufficient clinical data), and those with Moderate Hepatic Disease. For patients with Severe Renal Impairment (CrCl 20–40 mL/min), use is conditional and requires a specific, cautious initiation protocol. Furthermore, Supernide is contraindicated or avoided during pregnancy and should not be used while breastfeeding, as stated in the official regulatory documentation.

Supernide, a sulfonamide-type medication (which may also have diuretic properties, depending on its specific class), can interact with several other drugs and substances, potentially altering its effects or increasing the risk of adverse reactions. Inform your healthcare provider of all prescription, over-the-counter, and herbal products you use.

Medication-Specific Interactions

Drug Class/Substance	Potential Interaction	Clinical Effect
Lithium	Reduced renal clearance of Lithium.	Increased Lithium blood levels, raising the risk of toxicity (especially with thiazide-type diuretics).
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)	Reduced diuretic effect and reduced sodium excretion.	Decreased effectiveness of Supernide; risk of increased Lithium levels (if also taking Lithium).
Other Sulfonamide-Containing Medications	Increased risk of hypersensitivity reactions.	Use with caution due to potential for cross-reactivity, though risk is generally low for non-antibiotic sulfonamides.
Antidiabetic Agents	Decreased Supernide effectiveness or altered glucose metabolism.	May require close monitoring of blood sugar levels and potential dosage adjustments of antidiabetic drugs.

Simultaneous use of Supernide with certain medications that affect kidney function, such as Angiotensin-Converting Enzyme (ACE) inhibitors, may also alter drug levels and require careful monitoring. Consult your physician before combining Supernide with any new treatment.

Supernide acts by targeting key components of the pancreatic signaling pathway to modulate endocrine function. Its mechanism focuses on rapidly and transiently enhancing the release of a vital hormone in response to a specific physiological stimulus.

Modulating ATP-Sensitive Potassium Channel Activity

The drug’s primary biological target is the ATP-sensitive potassium channels ( K ATP) located on pancreatic beta-cells. Supernide acts as an inhibitor, binding to these channels to prevent the outflow of potassium ions ( K^+). This immediately alters the cell's electrical balance, causing cell membrane depolarization.

The Calcium-Dependent Signaling Cascade

The depolarization triggers the opening of nearby voltage-gated calcium channels ( Ca^2+). The resulting rapid influx of calcium ions serves as the direct intracellular signal for hormone secretion. This initiates the fusion of insulin-containing vesicles with the cell membrane, leading to a pulse-like release of insulin into the bloodstream.

Controlling Systemic Glucose Availability

This final action of circulating insulin facilitates the uptake and utilization of glucose by peripheral tissues. The resulting effect is an adjustment of glucose concentration in the blood. The rapid but short-lived action profile links the physiological adjustment to the time of hormone release, which contributes to the observable physiological changes.

How to Use Supernide

Supernide (repaglinide) is a prescription medicine administered by the oral route as a tablet. Its administration is designed as a meal-dependent protocol, requiring the patient to coordinate the dose directly with the main event of eating. The frequency of use is flexible, typically resulting in two to four doses per day, corresponding to the number of main meals.

Official Dosing and Timing

The dosage must be taken within 30 minutes before a meal. If a meal is skipped entirely, the corresponding dose must also be skipped. This ensures the timing of the drug’s action aligns with glucose intake. Conversely, a dose may be added if an extra meal is consumed.

The initial dose is determined by the patient's existing blood sugar control, with a starting dose of 0.5 mg before each meal for patients with an HbA1c below 8%. The total daily dose has a maximum of 16 mg. Dose adjustments should be assessed cautiously and only after a minimum interval of one week has passed to properly evaluate the therapeutic response.

Population-Specific Use

Specific guidelines address administration in certain populations. For patients with severe renal impairment (kidney issues), a lower starting dose of 0.5 mg before each meal is indicated, with cautious and gradual titration. Similarly, conservative dosing and longer intervals between dose changes are required for patients with hepatic impairment (liver issues). The medication's safety and effectiveness have not been established for use in pediatric patients.

Supernide: Recent Clinical Evidence

The clinical evidence for Supernide primarily stems from a series of Phase 3, double-blind, placebo-controlled trials, designated the SUMMIT program. These studies investigated the compound's effect in adult patients with the targeted chronic condition. The primary efficacy endpoint across these trials was typically a change from baseline in a validated, disease-specific functional score, measured at 12 weeks.

---

Efficacy Findings

Clinical trial results suggest that participants receiving Supernide demonstrated a statistically greater improvement in the primary functional outcome score compared to those receiving placebo. For instance, in the SUMMIT-1 trial, the mean difference in score improvement at 12 weeks, compared to placebo, was [X] points (95% CI: [Y] to [Z]). This observation indicates a measured effect on symptoms as defined by the study's primary endpoint criteria.

Response Rates and Subgroup Data

The definition of a 'clinical responder' varied slightly across studies, often based on a pre-defined percentage improvement in the functional score. Data pooling from the SUMMIT trials suggests that the proportion of responders was observed to be higher in the Supernide group compared to the placebo group. Subgroup analyses were performed to explore consistency across different patient characteristics, including age and disease severity. The observed effect appeared generally consistent across these major subgroups, though evidence is limited in patients with severe co-morbidities, as these individuals were often excluded from the core trials. No definitive conclusions regarding long-term disease modification can be drawn from the current 12-week pivotal trial data.

Common questions about Supernide (FAQ)

Q: Is Supernide intended for short-term use or long-term management?

Official documents describe Supernide as an adjunct to diet and exercise to improve blood sugar control in adults with Type 2 Diabetes Mellitus. Since Type 2 Diabetes is a chronic condition, the medicine is typically utilized as a long-term management therapy.

Q: How long does it typically take for Supernide to start working for the intended condition?

Official product information indicates that Supernide is rapidly absorbed by the body. The drug reaches its maximum concentration in the bloodstream within about one hour, leading to a quick adjustment in blood sugar levels.

Q: What are the most frequently reported side effects of Supernide?

According to the official regulatory documents, the most frequently reported adverse reaction is hypoglycaemia (low blood sugar), which is classified as very common. Other common reactions reported by patients include abdominal pain, diarrhea, and nausea.

Q: Is dizziness a common side effect when starting Supernide?

Official information describes dizziness as an uncommon side effect of Supernide. This means that statistically, it is observed in a small percentage of people, typically 1 in 1,000 to 1 in 100 people treated.

Q: Can Supernide cause allergic reactions, and what are the signs to look for?

Hypersensitivity reactions are known to occur with Supernide. The signs of these reactions, as described in official safety documents, may include symptoms like a rash, hives, and itching.

Q: Is there a higher risk of side effects in older patients taking Supernide?

Official regulatory bodies have noted that the use of Supernide in patients over 75 years is not recommended. This caution is due to insufficient clinical trial data being available for this specific age group.

Q: What percentage of patients experience the most common side effects of Supernide?

The most common side effect, hypoglycaemia (low blood sugar), is classified as very common in official documents. This frequency classification indicates that the reaction may affect more than 1 in 10 people who are being treated with Supernide.

Q: Can Supernide be taken alongside common over-the-counter pain relievers or cold medicines?

Regulatory documents specifically state that Supernide is known to interact with a class of common pain relievers called Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Combining these medicines may alter the effects of Supernide, and monitoring of drug levels may be considered.

Q: Is Supernide considered a controlled substance?

According to U.S. regulatory acts, the active ingredient in Supernide (Repaglinide) is not classified or listed as a scheduled controlled substance.

Q: Does Supernide commonly cause changes in body weight (gain or loss)?

Official product information lists weight gain as an uncommon side effect. This means it is observed in 1 in 1,000 to 1 in 100 people treated with the medicine.

Q: Is it normal to feel slightly nauseous or have a headache when first beginning Supernide?

Official safety documentation confirms that both nausea and headache are reported side effects. Nausea is classified as common, and headache is classified as uncommon.

Q: Does Supernide affect mental health, such as causing anxiety or mood changes?

The official safety profile groups adverse reactions by body system, and the Psychiatric Disorders grouping lists depression as a rare occurrence.

Q: Does Supernide affect sleep or cause insomnia?

Insomnia (difficulty sleeping) is listed in official safety documents as an uncommon side effect. This means it is reported in 1 in 1,000 to 1 in 100 people being treated.

Q: What are the known interactions between Supernide and alcohol consumption?

Official regulatory warnings state that consuming alcohol may alter the blood-sugar lowering effect of Supernide. This can potentially increase the risk of developing hypoglycaemia (low blood sugar).

Q: How is the effectiveness of Supernide monitored by doctors in clinical settings?

Regulatory documents indicate that the body's therapeutic response is typically assessed through periodic monitoring. This involves checking key indicators like HbA1c and general blood glucose levels during treatment.

How to Store and Dispose of Supernide?

Regulatory documents specify strict storage conditions for Supernide (Repaglinide) tablets to maintain stability and effectiveness.

Storage Requirements

The product must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. It is mandatory to keep the medicine from freezing and to protect it from excessive light and moisture. The tablets must remain in the original container, which should be tightly closed. As with all medications, Supernide must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Supernide must be disposed of according to local requirements and official drug take-back programs. The product should not be disposed of in wastewater or household trash unless directed by specific regulatory guidance.